665 related articles for article (PubMed ID: 10888615)
1. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
Ly A; Stamatatos L
J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
[TBL] [Abstract][Full Text] [Related]
2. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
Sagar M; Wu X; Lee S; Overbaugh J
J Virol; 2006 Oct; 80(19):9586-98. PubMed ID: 16973562
[TBL] [Abstract][Full Text] [Related]
4. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
5. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
[TBL] [Abstract][Full Text] [Related]
6. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
8. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
Saunders CJ; McCaffrey RA; Zharkikh I; Kraft Z; Malenbaum SE; Burke B; Cheng-Mayer C; Stamatatos L
J Virol; 2005 Jul; 79(14):9069-80. PubMed ID: 15994801
[TBL] [Abstract][Full Text] [Related]
9. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
[TBL] [Abstract][Full Text] [Related]
10. Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.
Painter SL; Biek R; Holley DC; Poss M
J Virol; 2003 Aug; 77(15):8448-61. PubMed ID: 12857914
[TBL] [Abstract][Full Text] [Related]
11. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
12. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
Foda M; Harada S; Maeda Y
Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
[TBL] [Abstract][Full Text] [Related]
13. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.
Ogert RA; Lee MK; Ross W; Buckler-White A; Martin MA; Cho MW
J Virol; 2001 Jul; 75(13):5998-6006. PubMed ID: 11390601
[TBL] [Abstract][Full Text] [Related]
14. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
[TBL] [Abstract][Full Text] [Related]
15. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
Maeda Y; Foda M; Matsushita S; Harada S
J Virol; 2000 Feb; 74(4):1787-93. PubMed ID: 10644351
[TBL] [Abstract][Full Text] [Related]
16. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
17. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
[TBL] [Abstract][Full Text] [Related]
18. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
Kato K; Sato H; Takebe Y
J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
[TBL] [Abstract][Full Text] [Related]
19. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.
Parrish NF; Wilen CB; Banks LB; Iyer SS; Pfaff JM; Salazar-Gonzalez JF; Salazar MG; Decker JM; Parrish EH; Berg A; Hopper J; Hora B; Kumar A; Mahlokozera T; Yuan S; Coleman C; Vermeulen M; Ding H; Ochsenbauer C; Tilton JC; Permar SR; Kappes JC; Betts MR; Busch MP; Gao F; Montefiori D; Haynes BF; Shaw GM; Hahn BH; Doms RW
PLoS Pathog; 2012; 8(5):e1002686. PubMed ID: 22693444
[TBL] [Abstract][Full Text] [Related]
20. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.
Kolchinsky P; Kiprilov E; Bartley P; Rubinstein R; Sodroski J
J Virol; 2001 Apr; 75(7):3435-43. PubMed ID: 11238869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
